Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Novo Nordisk (NVO) Stock Looks Below Fair Value Despite Recent Setbacks

📉 Novo Nordisk stock has fallen 36.4% over three years with a recent 0.9% return that underperforms peers.

💰 The company trades at a P/E of 11.1x, significantly below the industry average of 14.9x and peer average of 24.7x.

📊 A tailored fair P/E model estimates Novo Nordisk should trade at 23.0x, indicating it is undervalued by more than double.

⚠️ Recent setbacks include a failure in the ZEUS cardiovascular trial which may impact pipeline confidence.

⚖️ Ongoing legal action against Eli Lilly adds reputational and legal uncertainty to the company's valuation.

✅ Novo Nordisk passes 5 out of 6 valuation tests, suggesting the current price is conservative relative to benchmarks.

🗣️ Community sentiment narratives currently rate the stock as approximately 50% undervalued despite negative swings.

💡 Analysts note that low expectations may have already priced in some risks, leaving potential upside if fundamentals hold.

Bullish Signals
  • Novo Nordisk trades at a P/E multiple of 11.1x, which is well below the pharmaceutical industry average of 14.9x and peer group average of 24.7x.
  • The company's tailored fair P/E ratio is calculated at 23.0x, indicating the stock is undervalued by more than double its current market price.
  • Simply Wall St valuation screens show Novo Nordisk passing 5 out of 6 tests, suggesting the market price is conservative relative to fundamental benchmarks.
  • Community narratives identify multiple embedded options within the company's GLP-1 pipeline that could support future value despite current headwinds.
Risk Factors
  • The ZEUS trial failure may weigh on investor confidence regarding Novo Nordisk's cardiovascular development pipeline.
  • Ongoing legal action against Eli Lilly introduces specific legal and reputational uncertainty that investors factor into the company's valuation.
  • Novo Nordisk has experienced a significant share price decline of 36.4% over the past three years, reflecting weak overall returns for early buyers.
Full Analysis
Novo Nordisk (NVO) shares have declined significantly over the past three years, dropping 36.4%, with a more recent 0.9% return that lags behind industry peers. Despite these price movements and negative sentiment swings, the company currently trades at a P/E multiple of 11.1x, which is substantially lower than both the pharmaceuticals industry average of 14.9x and its peer group average of 24.7x. The article highlights that Novo Nordisk's tailored fair P/E ratio is estimated at 23.0x, suggesting the stock is undervalued by more than double its current market price. This valuation gap persists even after accounting for recent headwinds, including a setback in the ZEUS cardiovascular trial and ongoing legal action against competitor Eli Lilly. Simply Wall St analysis indicates that five out of six valuation tests support the view that Novo Nordisk is undervalued relative to its benchmarks. While the market has priced in risks related to the failed trial and legal disputes, the fundamental earnings anchor suggests a material disconnect between current share price and fair value based on profitability and scale. Investors are now focused on determining whether the current discount fully reflects the specific risks of the ZEUS trial outcome and the Eli Lilly lawsuit, or if further downside pressure remains. The consensus narrative from the community suggests the company is approximately 50% undervalued, citing low expectations and embedded options within its GLP-1 pipeline.